Raymond James lowered the firm’s price target on Johnson & Johnson to $165 from $170 and keeps an Outperform rating on the shares. J&J’s Q4 results were solid, and its initial 2025 EPS guidance was slightly higher than expected, though Med Tech remains soft, the analyst tells investors in a research note. More active M&A should help the longer-term growth profile, but the Stelara loss of exclusivity will weigh on near-term growth optics, the firm says. At the same time, Raymond James thinks much of the bad news is factored into the stock.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target lowered to $155 from $170 at Stifel
- Johnson & Johnson price target lowered to $159 from $160 at BofA
- Johnson & Johnson price target lowered to $163 from $175 at Morgan Stanley
- Johnson & Johnson price target lowered to $158 from $160 at Bernstein
- Johnson & Johnson publishes nipocalimab study results in The Lancet Neurology